Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
carboplatin
chemotherapy
childhood cancer
dosing regimen
therapeutic drug monitoring
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
06
03
2020
revised:
27
04
2020
accepted:
30
04
2020
pubmed:
11
6
2020
medline:
29
7
2021
entrez:
11
6
2020
Statut:
ppublish
Résumé
The widely used platinum agent carboplatin represents a good example of an anticancer drug where clear relationships between pharmacological exposure and clinical response and toxicity have previously been shown. Within the setting of childhood cancer, there are defined groups of patients who present a particular challenge when dosing with carboplatin, including neonates and infants, those who are anephric, and poor prognosis patients receiving high-dose chemotherapy. For these groups, nonstandard chemotherapy dosing regimens are currently utilised, often with different approaches between clinical study protocols and between treatment centres. For the treatment of these patient populations in the UK, there is now significant experience in carrying out therapeutic drug monitoring, aiming to consistently achieve target drug exposures, maximise drug efficacy and minimise treatment-related side effects. An ongoing clinical trial is currently providing information on drug exposure for a wide range of anticancer agents in these hard to treat patient populations. In addition to supporting dosing decisions for individual patients, the collection and analysis of these data may allow the development of future dosing regimens. For example, current reduced dosing approaches for neonates and infants based on age or body weight, may well be better replaced by regimens based on a sound pharmacological rationale. The successful use of adaptive carboplatin dosing in childhood cancer should encourage the development of therapeutic drug monitoring approaches more widely in an oncology setting.
Substances chimiques
Antineoplastic Agents
0
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-262Subventions
Organisme : Department of Health
ID : PB-PG-1216-20032
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : PB-PG-1216-20032
Organisme : ECMC
ID : C9380/A25169
Organisme : Cancer Research UK
ID : C9380/A25138
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Bardin C, Veal G, Paci A, et al. Therapeutic drug monitoring in cancer - are we missing a trick? Eur J Cancer. 2014;50(12):2005-2009.
Egorin MJ, Olman EA, Van Echo DA, et al. Pharmacokinetics and dosage reduction of c/s-diammine(1, 1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44(11):5432-5438.
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985;12(Suppl A):51-57.
Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520-528.
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985;45(12 Pt 1):6502-6506.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756.
Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's cancer study group. J Clin Oncol. 1993;11(12):2314-2323.
Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom Children's cancer study group trial. J Clin Oncol. 2000;18(21):3614-3621.
Allen S, Wilson MW, Watkins A, et al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. Ped Blood Cancer. 2010;55:47-54.
Adamson PC, Veal GJ, Womer RB, et al. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine based estimates of renal function. Ped Blood Cancer. 2019;66(6):1-8, e27672. https://doi.org/10.1002/pbc.27672
Duong JK, Veal GJ, Nath CE, et al. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol. 2019;85(1):136-146.
Motzer RJ, Niedzwiecki D, Isaacs M, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 1990;27(3):234-238.
Picton SV, Keeble J, Holden V, Errington J, Boddy AV, Veal GJ. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol. 2009;63(4):749-752.
Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol. 2010;65(6):1057-1066.
Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034-1041.
Huitema ADR, Spaander M, Mathot RAA, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol. 2002;13(3):374-384.
Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800-805.
Barnham KJ, Djuran MI, Murdoch PS, Ranford JD, Sadler PJ. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg Chem. 1996;35(4):1065-1072.
Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer. 1995;31A(11):1804-1810.
Smits C, Swen SJ, Theo Goverts S, Moll AC, Imhof SM, Schouten-van Meeteren AY. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer. 2006;42(4):492-500.
Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50(2):223-226.
Jehanne M, Lumboso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637-643.
Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol. 2012;30(10):1023-1024.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action and therapy in infants and children. New Engl J Med. 2003;349(12):1157-1167.
Veal GJ, Errington J, Hayden J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022-2030.
Thomas F, Veal GJ, El Balkhi S, et al. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol. 2018;82(2):361-365.
ISRCTN 10139334. Therapeutic drug monitoring in children with cancer. https://doi.org/10.1186/ISRCTN10139334. Accessed February, 2020.
Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995;36(4):345-351.
Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1 - Cytotoxics. Eur J Cancer. 2014;50(12):2010-2019.
Veal GJ, Errington J, Tilby MJ, et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high dose carboplatin for the treatment of solid tumours. Br J Cancer. 2007;96(5):725-731.
Kloft C, Siegert W, Jaehde U. Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. Br J Cancer. 2003;89(5):787-794.
Moeung S, Chevreau C, Broutin S, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicentre study. Clin Cancer Res. 2017;23(23):7171-7179.
Koren G, Weitzman S, Klein J, Moselhy G. Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function. Med Pediatr Oncol. 1993;21(5):368-372.
Kodama J, Sasaki A, Masahiro S, et al. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncol Lett. 2010;1(3):511-513.
Wada T, Fukuda T, Kawanishi M, et al. Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: a case report. Biomed Rep. 2016;5(2):199-202.
Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol. 2002;84(2):335-338.
Fong MK, Fetterly GJ Jr, McDougald LJ, Iyer RV. Carboplatin pharmacokinetics in a patient receiving hemodialysis. Pharmacotherapy. 2014;34(2):e9-e13.
English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer. 1996;73(6):776-780.
Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol. 2004;54(4):295-300.
Rubie H, Doz F, Vassal G, et al. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur J Cancer. 2003;39(10):1433-1438.
Moeung S, Chevreau C, Poinsignon V, et al. Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoring. Ther Drug Monitor. 2019;41(1):66-74.
White-Koning M, Paludetto MN, Le Louedec F, et al. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemother Pharmacol. 2020;85(3):585-592.